Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Accelerate Diagnostics's Gross Margin % or its related term are showing as below:
MEX:AXDX's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 52.44 * Ranked among companies with meaningful Gross Margin % only.
Accelerate Diagnostics had a gross margin of 15.94% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Accelerate Diagnostics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Accelerate Diagnostics had a gross margin of 15.94% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Accelerate Diagnostics Gross Margin % Related Terms
Accelerate Diagnostics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AXDX vs MSIU, BIOLQ, AFIB: Gross Margin % Comparison
For the Medical Devices subindustry, Accelerate Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Accelerate Diagnostics (MEX:AXDX) has a Gross Margin % of 15.94% as of Dec. 2024. Gross margin is the ratio of total gross profit to net sales. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Gross Margin % too high?
Accelerate Diagnostics' current Gross Margin % is 15.94%. The Medical Devices & Instruments industry median Gross Margin % is 52.44. Accelerate Diagnostics' value of 15.94% is 69.6% below this industry median. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Gross Margin % compare to MSIU and BIOLQ?
Accelerate Diagnostics' Gross Margin % of 15.94% can be compared against companies in the Medical Devices & Instruments industry. The industry median Gross Margin % is 52.44. Accelerate Diagnostics' value of 15.94% is 69.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.44, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accelerate Diagnostics's current Gross Margin % of 15.94% is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Accelerate Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accelerate Diagnostics's current Gross Margin % is 15.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Gross Margin % of 15.94%. The current Gross Margin % is 15.94% and 69.6% below the Medical Devices & Instruments industry median of 52.44. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Gross Margin % is 15.94% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
